Annovis Bio (ANVS)
(Delayed Data from NYSE)
$18.01 USD
+4.41 (32.43%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $17.66 -0.35 (-1.94%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum D VGM
Annovis Bio, Inc. (ANVS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$35.40 | $72.00 | $13.00 | 160.29% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Annovis Bio, Inc. comes to $35.40. The forecasts range from a low of $13.00 to a high of $72.00. The average price target represents an increase of 160.29% from the last closing price of $13.60.
Analyst Price Targets (5 )
Broker Rating
Annovis Bio, Inc. currently has an average brokerage recommendation (ABR) of 1.40 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.40 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, four are Strong Buy, representing 80% of all recommendations. A month ago, Strong Buy represented 80%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.40 | 1.40 | 1.40 | 1.40 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/21/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
2/28/2024 | Brookline Capital Markets | Tyler Bussian | Strong Buy | Hold |
12/29/2023 | Canaccord Genuity | Sumant Kulkarni | Not Available | Strong Buy |
10/20/2023 | Maxim Group | Jason Mccarthy | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.40 |
ABR (Last week) | 1.40 |
# of Recs in ABR | 5 |
Average Target Price | $35.40 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | -0.87 |